Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore. Excepteur sint lorem cupidatat.

You may like:

The Space Between: Connecting the Science of Targeted PsA Therapies to Patient Care

The Space Between: Connecting the Science of Targeted PsA Therapies to Patient Care

This online activity explores mixed-reality content on targeted therapies for psoriatic arthritis (PsA). It includes concise presentations on the PsA treatment landscape and patient-centered care and features a demonstration of shared decision making conversation. 

  • Dr. Deodhar, Professor of Medicine, Oregon Health & Science University

    Atul A. Deodhar, MD, MRCP, FACR, FACP
    Professor of Medicine,
    Medical Director of Rheumatology Clinics,
    Division of Arthritis & Rheumatic Diseases
    Oregon Health & Science University
    Portland, Oregon

  • Dr. Desai, Chief of Rheumatology, University of California, Irvine

    Sheetal Desai, MD, MSEd
    Chief of Rheumatology,
    Rheumatology Fellowship Program Director,
    Director, Lupus Clinic
    Associate Clinical Professor of Medicine,
    Division of Rheumatology
    University of California, Irvine
    Irvine, California

  • Joseph Merola, MD, MMSc
    Associate Professor, Harvard Medical School
    Vice Chair of Clinical Trials and Innovation, Dermatology
    Director, Center for Skin and Related Musculoskeletal Diseases
    Director, Clinical Unit for Research Innovation and Trials (CUReIT), Dermatology
    Departments of Dermatology and Medicine
    Division of Rheumatology
    Associate Program Director, Combined Medicine-Dermatology Residency Program
    Brigham and Women’s Hospital
    Boston, Massachusetts

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the launch of this activity.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative): Marianna Shershneva, MD, PhD and Sydney Pate, MS 
  • Planner: Alfred Martin, MD  
  • Planner: Svetlana Dambaeva, MD  
  • Planner: Linda Grinnell-Merrick, MS, NP-BC 

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months: 

  • Planner: April W. Armstrong, MD, MPH has received a consulting fee from Abbvie, Janssen, Eli Lilly, Pfizer, Ortho Dermatologics, Sanofi Genzyme Regeneron, Bristol-Myers Squibb, Dermavant, Science 37, Modernizing Medicine, LEO Pharma, and Novartis. Dr. Armstrong has contracted research for Janssen, Eli Lilly, UCB Biopharma, Dermira, Bristol-Myers Squibb, LEO Pharma, Novartis, and Kyowa Hakko Kirin. 
  • Planner: Philip J. Mease, MD has received a consulting fee for AbbVie, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, and UCB. Dr. Mease has participated on a speaker’s bureau for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Genentech, Janssen, Lilly, Novartis, Pfizer, and UCB and has contracted research for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Janssen, Lilly, Novartis, Pfizer, Sun, and UCB.  
  • Presenter: Sheetal Desai, MD, MSEd has received a consulting fee for Janssen and has participated in a speaker’s bureau for Janssen. 
  • Presenter: Atul A. Deodhar, MD, MRCP, FACR, FACP has received a consulting fee for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Glaxo Smith & Klein, Janssen, Novartis, Pfizer, and UCB. Dr. Merola has participated on an advisory board for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Glaxo Smith & Klein, Janssen, Novartis, Pfizer, and UCB; he has contracted research for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Glaxo Smith & Klein, Janssen, Novartis, Pfizer, and UCB 
  • Presenter: Joseph Merola, MD, MMSc is a consultant for Merck Research Laboratories, Abbvie, Dermavant, Eli Lilly and Company, Novartis, Janssen, UCB, Celgene, Sanofi Regeneron, Almirall, Sun Pharma, Biogen, Pfizer, Incyte, Aclaris, and EMD Sorono. Dr. Merola is also an Investigator for Leo Pharma and Kyowa Kirin.   

As a result of participation in this educational activity, participants should increase their ability to:

  • Describe

    Describe a current model explaining psoriatic arthritis (PsA) pathophysiology and mechanisms of action of targeted therapies for PsA

  • Apply evolving treatment strategies and evidence of effectiveness and safety of targeted therapies for management of patients with PsA 

  • Discuss

    Discuss the impact of different PsA disease domains on the patient’s quality of life and patient-reported outcomes measures 

  • Engage patients with PsA in shared decision making regarding treatment goals, treatment plan, and treatment modification 

Activity Information

Target Audience
The target audience for this activity is rheumatologists and NP/PA rheumatology providers. Other healthcare professionals who treat patients with PsA may benefit form participation.

Accreditation Statement
Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Forefront Collaborative designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is approved for 1.25 contact hour(s) of continuing education (which includes up to 0.75 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 19114026. This activity was planned in accordance with AANP Accreditation Standards and Policies.

IPMA is approved by the California Board of Registered Nursing, Provider Number 6971, for 1.25 contact hours. Each person should retain this certificate for 4 years after the course has been completed.

CME Content Review
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, Interstate Postgraduate Medical Association, or Lilly.

The content of this activity was independently peer reviewed by two reviewers and two patients with psoriasis and psoriatic arthritis. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity may include reference to unlabeled or unapproved uses of drugs or devices.

This activity is provided by Forefront Collaborative in collaboration with Interstate Postgraduate Medical Association.

Commercial Support
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.